• 1
    Regier DA, Boyd JH, Burke J, et al. One month prevalence of mental disorders in the United States. Arch Gen Psychiatry. 1988;45:97786.
  • 2
    Kessler R, McGonagle K, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:819.
  • 3
    Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry. 2000;157:66982.
  • 4
    Johnson J, Weissman M, Klerman G. Panic disorder, comorbidity, and suicide attempts. Arch Gen Psychiatry. 1990;47:8058.
  • 5
    Leon A, Olfson M, Broadhead W, et al. Prevalence of mental disorders in primary care: implications for screening. Arch Fam Med. 1995;4:85761.
  • 6
    Kawachi I, Sparrow D, Vokonas PS, Weiss ST. Coronary heart disease/myocardial infarction: symptoms of anxiety and risk of coronary heart disease: the normative aging study. Circulation. 1994;90:22259.
  • 7
    Fifer SK, Mathias SD, Patrick DL, Mazonson PD, Lubeck DP, Buesching DP. Untreated anxiety among adult primary care patients in a health maintenance organization. Arch Gen Psychiatry. 1994;51:74050.
  • 8
    DuPont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ. Economic costs of anxiety disorders. Anxiety. 1996;2:16772.DOI: 10.1002/(sici)1522-7154(1996)2:4<167::aid-anxi2>;2-l
  • 9
    Greenberg P, Sisitsky T, Kessler Rea. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999;60:42735.
  • 10
    Costa E, Silva JA. The public health impact of anxiety disorders: a WHO perspective. Acta Psychiatrica Scandinavica. 1998;98:2S5S.
  • 11
    Skaer TL, Robison LM, Sclar DA, Galin RS. Trend in complaint, diagnosis, use of pharmacotherapy and diagnosis of comorbid depression. Clin Drug Invest. 2000;20:23744.
  • 12
    Bryant E, Shimizu I. Sampling design, sampling variance, and estimation procedures for the National Ambulatory Medical Care Survey. Vital Health Stat. 1988;108:139.
  • 13
    U.S. Department of Health and Human Services PHS. Health Care Financing Administration. International Classification of Diseases, 9th Revision, Clinical Modification Third Edition. Washington DC: U.S. Department of Health and Human Services; 1989.
  • 14
    Potthoff R, Woodbury M, Manton K. “Equivalent sample size” and “ equivalent degrees of freedom” refinements for inference using survey weights under superpopulation models. J Am Stat Assoc. 1992;87:38396.
  • 15
    Leaf P, Myers J, McEvoy L. Procedures used in the epidemiologic catchment area study. New York, NY: The Free Press; 1991.
  • 16
    Barrett JE, Barrett HA, Oxman TE, Gerber PD. The prevalence of psychiatric disorders in a primary care practice. Arch Gen Psychiatry. 1988;45:11006.
  • 17
    Nisenson LG, Pepper CM, Schwenk TL, Coyne JC. The nature and prevalence of anxiety disorders in primary care. Gen Hosp Psychiatry. 1998;20:218.
  • 18
    Olfson M, Shea S, Feder A, et al. Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. Arch Fam Med. 2000;9:87683.
  • 19
    Harman JS, Mulsant BH, Kellcher KJ, Schulberg HC, Kupfer DJ, Reynolds CF. Narrowing the gap in treatment of depression. Int J Psychiatry Med. 2001;31:25569.
  • 20
    Shear MK, Greeno C, Kang J, et al. Diagnosis of nonpsychotic patients in community clinics. Am J Psychiatry. 2000;157:5817.
  • 21
    Young AS, Klap R, Sherbourne CD, Wells KB. The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry. 2001;58:5561.